Ocugen CEO to Lead Key Panels on Biotech Financing and Gene Therapy Commercialization
Event summary
- Ocugen CEO Dr. Shankar Musunuri to moderate panel on biotech financing at H.C. Wainwright's Biotech on Tap 2026 in Munich on October 1, 2026.
- Musunuri to participate in gene therapy commercialization panel at Cell & Gene Meeting on the Mesa in Phoenix on October 6, 2026.
- Company focuses on modifier gene therapies for blindness diseases, targeting conditions like retinitis pigmentosa and geographic atrophy.
- Ocugen's platform addresses multiple gene networks, differentiating from traditional single-gene therapies.
The big picture
Ocugen's participation in these high-profile conferences underscores the growing importance of strategic financing and commercialization pathways in the gene therapy sector. As the company advances its modifier gene therapy platform, its ability to secure alternative funding and navigate regulatory hurdles will be critical to its success in addressing large patient populations with unmet medical needs. The biotech financing panel in particular highlights the industry's increasing focus on non-traditional funding mechanisms to support innovative therapies.
What we're watching
- Financing Strategy
- How Ocugen will leverage alternative financing solutions discussed at H.C. Wainwright conference to advance its pipeline.
- Regulatory Pathways
- The pace at which Ocugen can navigate approval processes for its modifier gene therapies.
- Market Positioning
- Whether Ocugen can differentiate itself in the competitive gene therapy space through its gene-agnostic approach.
Related topics